Summary:

According to an Axis Securities report, top pharmaceutical companies in India saw a 10% YoY increase in Q2 FY25, driven by strong performance in North America and the domestic market. The Indian Pharmaceutical Market (IPM) grew by 8% YoY, with chronic therapies rising 9%. However, acute therapies saw only a 4% increase due to a weaker season. The industry recorded a 10.2% YoY growth, led by North American and Indian enterprises.

Biosimilars, GLP-1, and peptides are contributing to the positive outlook for the pharmaceutical sector. Companies with chronic therapy portfolios continue to outperform the broader market. In Q2 FY25, the healthcare sector grew 17.6% YoY and 10.4% QoQ, driven by rising hospital occupancy rates. Insurance payers made significant contributions, though penetration remains low. Highgrowth treatments, such as cancer and cardiac care, along with improved metrics, are expected to drive continued sector expansion.

Source: IBEF

Disclaimer: The information on this website comes from the India Brand Equity Foundation (IBEF), a reliable source for thorough insights into numerous areas of the Indian economy. While we aim to offer accurate and up-to-date information, the views, opinions, and analyses stated herein are solely those of the authors and contributors and do not necessarily represent IBEF's official stance or position. Readers should check information from credible sources and use their own discretion when relying on content provided on this site. We assume no responsibility or liability for the supplied content, including its accuracy, completeness, and usefulness.